You are here: Industry Insights > Fosun pharma

News List

BioNTech, Fosun Pharma initiate Covid-19 vaccine candidate trial in China pharmaceutical-technology
November 27, 2020
BioNTech and Shanghai Fosun Pharmaceutical (Fosun Pharma) have initiated Phase II clinical trial of their lead mRNA Covid-19 vaccine candidate, BNT162b2, in Taizhou and Lianshui, Jiangsu Province, China.
China gives the go-ahead for human trials of BioNTech’s COVID vaccine candidate expresspharma
July 20, 2020
China has approved an early-stage trial in humans of German firm BioNTech’s experimental COVID-19 vaccine, its local partner Shanghai Fosun Pharmaceutical said.
Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA prnasia
July 14, 2020
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.
BioNTech teams up with Fosun Pharma to test Covid-19 mRNA vaccine in China — and scores $50M investment endpts
March 17, 2020
Having quietly launched its own mRNA vaccine efforts against the novel coronavirus to match the higher profile campaigns of Moderna and CureVac ...
Revance Announces China Market License Agreement with Fosun Pharma for RT002 pharmafocusasia
December 05, 2018
Revance Therapeutics, Inc., a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions....
Ardelyx signs license agreement with Fosun Pharma for tenapanor in China manufacturing.pharmaceutical-business-review
December 13, 2017
Ardelyx has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company (Fosun Pharma) for tenapanor.
China’s Fosun Pharma takeover of an Indian pharma giant biospectrumasia
October 27, 2017
The deal will help the Chinese company make inroads into India, gain access to US injectable drug market where Gland has a firm hold and bolster its product portfolio
Fosun Pharma acquires 74 per cent stake in Gland Pharma for $1.09 bn expressbpd
October 09, 2017
Chinese drug firm Fosun Pharma has acquired approximately 74 per cent in Hyderabad-based Gland Pharma at a valuation of not more than $1.09 billion, the company has said.
Fosun Pharma to acquire 74 per cent stake in Gland Pharma expressbpd
September 19, 2017
In a filing on Hong Kong, S.A.R., China stock exchange, Shanghai Fosun Pharmaceutical Group said the relevant parties have entered into certain amendments to the transaction documents